[Concentrated antihemophilic globulin in the treatment of hemorrhagic syndromes].
The author presented the general informations on the preparation of the Factor VIII and Factor IX concentrates, on their use and side effects. Special attention was paid to the resolutions of the Scientific group on the Inherited Blood Clotting Disorders, in the meeting of the World Health Organization, which was held in Geneva, 1972.
D000347:Afibrinogenemia / Q000628:therapy; D001778:Blood Coagulation Disorders / Q000628:therapy*; D005164:Factor IX / Q000627:therapeutic use*; D005165:Factor V / Q000627:therapeutic use; D005166:Factor V Deficiency / Q000628:therapy; D005169:Factor VIII / Q000627:therapeutic use*; D005170:Factor X / Q000627:therapeutic use; D005171:Factor X Deficiency / Q000628:therapy; D006467:Hemophilia A / Q000628:therapy; D002836:Hemophilia B / Q000628:therapy; D006801:Humans
D005165:Factor V; D005169:Factor VIII; D005164:Factor IX; D005170:Factor X
Koncentrovani antihemofilni globulini u lecenju hemoragijskih sindroma